
==== Front
Surg Case Rep
Surg Case Rep
Surgical Case Reports
2198-7793
Springer Berlin Heidelberg Berlin/Heidelberg

39294428
2010
10.1186/s40792-024-02010-9
Case Report
Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report
Saegusa Yoshitaka 1
http://orcid.org/0000-0002-6881-4305
Akabane Shintaro akabanes@hiroshima-u.ac.jp

1
Shimomura Manabu 1
Okuda Hiroshi 1
Yano Takuya 1
Mochizuki Tetsuya 1
Inoue Wako 1
Yamaguchi Mizuki 1
Yamaguchi Shinji 1
Sentani Kazuhiro 2
Yamauchi Masami 3
Tokumo Kentaro 3
Ohdan Hideki 1
1 https://ror.org/03t78wx29 grid.257022.0 0000 0000 8711 3200 Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan
2 https://ror.org/03t78wx29 grid.257022.0 0000 0000 8711 3200 Department of Molecular Pathology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan
3 https://ror.org/038dg9e86 grid.470097.d 0000 0004 0618 7953 Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan
19 9 2024
19 9 2024
12 2024
10 22024 7 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Rectal neuroendocrine carcinomas (NECs) are rare and associated with poorer prognoses compared to conventional adenocarcinomas. The efficacy of adjuvant chemotherapy for resectable rectal NECs remains uncertain. Herein, we present a case of rectal NEC successfully treated with postoperative chemotherapy using irinotecan plus cisplatin.

Case presentation

A 48-year-old woman with a history of endometrial cancer presented with an intramural rectal tumour detected on follow-up imaging. Colonoscopy revealed a 30 mm submucosal tumour, and laparoscopic low anterior resection was performed. Histopathological examination showed poorly differentiated atypical cells with solid growth patterns. Metastasis from the uterine cancer was ruled out due to histological differences between the primary uterine tumour and the rectal lesion, as well as the absence of hormone receptor immunohistochemical expression. Further immunohistochemical analysis revealed diffuse CD56 positivity, a high mitotic rate (> 20/10 high power fields) and a Ki-67 labelling index exceeding 70%. Based on these findings, a diagnosis of rectal NEC, T3N0M0, Stage IIB (UICC 8th edition), was established. Given the aggressive nature of the tumour evidenced by a high Ki-67 labelling index, adjuvant chemotherapy comprising six cycles of irinotecan plus cisplatin was administered to mitigate the risk of recurrence. At the 3-year follow-up, the patient was free of disease recurrence.

Conclusion

This case highlights the importance of multidisciplinary surgical interventions followed by adjuvant chemotherapy in managing rectal NECs.

Keywords

Neuroendocrine carcinomas
Adjuvant chemotherapy
Irinotecan
Cisplatin
Case report
http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science 23K15498 Akabane Shintaro issue-copyright-statement© Japan Surgical Society 2024
==== Body
pmcBackground

Rectal neuroendocrine carcinomas (NECs) are rare tumours with more aggressive behaviour and poorer prognosis than conventional adenocarcinomas [1]. Several studies have demonstrated the efficacy of cisplatin-based chemotherapy for advanced gastrointestinal NECs [2]. For the treatment of resectable rectal NECs, surgery alone is not preferable, and adjuvant chemotherapy needs to be employed considering the potential malignancy. However, no regimens have been established to date. Herein, we describe a case of rectal NEC treated with laparoscopic resection and sequential chemotherapy with irinotecan plus cisplatin (IP).

Case presentation

A 48-year-old woman with a history of total hysterectomy and bilateral salpingo-oophorectomy for stage IA endometrial cancer (UICC 8th edition) showed an intramural tumour in the rectum on follow-up CT scan (Fig. 1a). Colonoscopy revealed a 30 mm-sized submucosal tumour (Fig. 1b), and a subsequent biopsy showed a moderately differentiated adenocarcinoma. Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET–CT) scans were also conducted (images not shown), estimating the preoperative stage as cT3N0M0, corresponding to stage IIA (UICC 8th edition). We performed laparoscopic low anterior resection with D3 lymph node dissection, and the surgical specimen showed a submucosal tumour with ulceration 3.5 × 2.5 cm in size (Fig. 1c). The patient was discharged without major complications 9 days postoperatively.Fig. 1 Images of the rectal tumour. a CT tomography revealed an intramural tumour in the rectum. b Colonoscopy reveals a submucosal tumour. c Resected specimen showing a submucosal tumour with ulceration

Histopathological examination revealed poorly differentiated, proliferating, atypical cells with solid growth patterns. A metastatic tumour from the uterine cancer was deemed unlikely because of histological discrepancies between the primary uterine tumour and the rectal lesion, as well as the absence of oestrogen and progesterone receptor expression (Fig. 2). Immunohistochemical analysis revealed positivity for CK7 and negativity for CK20 and CDX2 (data not shown). The cytokeratin staining pattern did not indicate conventional rectal adenocarcinoma, and microsatellite unstable rectal cancer was suspected considering the poorly differentiated histology [3]. As this patient met the criteria of the Bethesda Guidelines 2004, we also needed to exclude the possibility of Lynch syndrome. We then performed immunostaining for mismatch repair (MMR) proteins and found that the MMR protein expression was intact (data not shown), indicating that the tumour developed due to factors other than microsatellite instability [4]. Further immunohistochemical analysis demonstrated diffuse CD56 positive expression, negative for synaptophysin and chromogranin A. Mitotic activity was more than 20/10 high power fields and the Ki-67 labelling index was more than 70% in the tumour cells (Fig. 3). From these findings, we diagnosed neuroendocrine carcinoma of the rectum pT3N0M0, Stage IIB (UICC 8th edition). Although there were no lymph node metastases, the risk of recurrence was high because of the high Ki-67 labelling index. Consequently, we administered six courses of adjuvant chemotherapy with IP. The patient experienced G3 neutropenia, the overall adverse effects were manageable, and the treatment regimen was safely completed. The patient remained alive and recurrence free at the follow-up of 3 years.Fig. 2 Pathological findings differentiating from endometrial cancer. a Well-differentiated endometrioid adenocarcinoma limited to the endometrium (H&E staining ×100). b Solidary proliferation of atypical cells was observed in the rectal tumour (H&E staining ×100). Carcinoma cells were negative for oestrogen receptor (c) and progesterone receptor (d) (×100)

Fig. 3 Pathological diagnosis for rectal neuroendocrine carcinoma. Microscopic findings of the rectal tumour (a H&E staining ×40, b H&E staining ×400). c Carcinoma cells are diffuse positive for CD56 (on immunohistochemistry, ×100). d Ki-67 labelling index > 70% in tumour cells (on immunohistochemistry, ×100)

Discussion

This case report describes the favourable clinical course of a patient with rectal NEC who underwent surgical resection and subsequent adjuvant chemotherapy. Evidence of treatment strategies for rectal NEC is lacking because of the extremely low incidence of this disease [5]. This report supports accumulating evidence for the combination of radical resection and systemic chemotherapy as a treatment strategy for rectal NEC.

Neuroendocrine neoplasms (NENs) were formerly known as carcinoids; however, the understanding of the disease is ambiguous. However, as pathological investigations progressed, the recognition of diverse grades led to the proposal of the 2010 WHO Classification [6]. NENs with poorly differentiated histology and a Ki-67 index > 20% were designated as neuroendocrine carcinomas. Gastrointestinal NECs exhibit a poor prognosis owing to their biological malignancy and propensity for metastasis, showing morphological features similar to those of small cell carcinomas of the lung [7]. In this case, biopsy tissue at the time of preoperative endoscopy showed that the tumour tissue was consistent with a moderately differentiated adenocarcinoma, and there were no findings that would raise active suspicion of NEC. The difficulty in preoperative diagnosis may be attributed to the submucosal localisation of the tumour, and previous report suggests that the positive diagnosis rate is as low as 60% [1].

Bernick et al. reported that colorectal NECs have a poor prognosis, with a median survival of only 10.4 months, indicating the necessity for multidisciplinary treatment [1]. Further evidence showed that patients with a higher Ki-67 index had longer overall survival with platinum-based therapy than those with a lower Ki-67 index in advanced gastrointestinal NEC [8]. Several case reports demonstrated the efficacy of perioperative chemotherapy for colorectal NECs following surgical resection [7, 9, 10]. Large database analyses suggest that adjuvant chemotherapy extends overall survival in colorectal neuroendocrine carcinomas following curative resection, regardless of the disease stage [11]. In a retrospective analysis involving lymph node-negative cases of rectal NECs, it was demonstrated that the median overall survival was 1.0 year for surgery alone, whereas it was 2.5 years for patients treated with adjuvant chemotherapy [12]. Given the shared micromorphological features of small cell lung cancer, treatment regimens for pancreatic and gastrointestinal neuroendocrine carcinomas are influenced by those for small cell lung cancers, with cisplatin-based adjuvant chemotherapy recommended following resection [13].

There is still much debate regarding the appropriate regimens for colorectal NECs. A phase 3 randomised clinical trial for advanced neuroendocrine carcinomas of the digestive system conducted in Japan determined that both IP and cisplatin plus etoposide (EP) were suitable standard treatments, demonstrating no significant superiority over the others [2]. Nevertheless, in another clinical trial conducted for advanced small cell lung cancer, IP was superior to EP [14].

In our case, we selected the IP regimen based on these considerations and administered it post-operatively, yielding favourable outcomes. Although there are several reports of long-term survival with multidisciplinary treatment for colorectal neuroendocrine carcinomas [15, 16], issues regarding the choice of multimodal treatment remain unclear. A treatment strategy with the accrual of additional cases needs to be formulated. It is necessary to establish higher level of evidence by large-scale clinical trials for colorectal NECs, including cases without lymph node metastases.

Conclusion

This case report describes a rectal NEC that was successfully treated with surgical resection, followed by adjuvant chemotherapy with an IP regimen. This case highlights the importance of a multidisciplinary treatment for resectable gastrointestinal NECs.

Abbreviations

NEC Neuroendocrine carcinoma

CT Computed tomography

UICC Union for International Cancer Control

IP Irinotecan plus cisplatin

EP Cisplatin plus etoposide

Acknowledgements

We would like to thank Editage (www.editage.com) for the English language editing.

Author contributions

YS, SA, and HO2 were responsible for the conception and designed the study. SY and SA drafted the manuscript. MS and HO2 reviewed and edited the manuscript. WI, MY1, and SY acquired the data. YS, SA, HO1, TY, and TM participated in the surgical treatment. MY2 and KT administered the adjuvant chemotherapy. SA and KS were responsible for the pathological analysis. All the authors have read and approved the final version of the manuscript.

Funding

This study was supported by the Japan Society for the Promotion of Science (Grant Number 23K15498).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Informed consent was obtained from the patient for the presentation of the details of this case along with images for publication purposes. No personal identification information is displayed on the images.

Competing interests

The authors have no conflict of interest to declare.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Bernick PE Neuroendocrine carcinomas of the colon and rectum Dis Colon Rectum 2004 47 2 163 169 10.1007/s10350-003-0038-1 15043285
Bernick PE, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47(2):163–9.15043285
2. Morizane C Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial JAMA Oncol 2022 8 10 1447 1455 10.1001/jamaoncol.2022.3395 35980649
Morizane C, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 2022;8(10):1447–55.35980649
3. Lugli A Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status Mod Pathol 2008 21 11 1403 1412 10.1038/modpathol.2008.117 18587323
Lugli A, et al. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008;21(11):1403–12.18587323
4. Stelow EB Moskaluk CA Mills SE The mismatch repair protein status of colorectal small cell neuroendocrine carcinomas Am J Surg Pathol 2006 30 11 1401 1404 10.1097/01.pas.0000213272.15221.38 17063080
Stelow EB, Moskaluk CA, Mills SE. The mismatch repair protein status of colorectal small cell neuroendocrine carcinomas. Am J Surg Pathol. 2006;30(11):1401–4.17063080
5. Zhou J Small cell carcinoma of the rectum: a report of imaging results from four cases Oncol Lett 2016 11 3 1671 1676 10.3892/ol.2016.4136 26998060
Zhou J, et al. Small cell carcinoma of the rectum: a report of imaging results from four cases. Oncol Lett. 2016;11(3):1671–6.26998060
6. Rindi G Petrone G Inzani F The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction Endocr Pathol 2014 25 2 186 192 10.1007/s12022-014-9313-z 24699927
Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25(2):186–92.24699927
7. Nojima H Advanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation World J Surg Oncol 2010 8 29 10.1186/1477-7819-8-29 20398400
Nojima H, et al. Advanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation. World J Surg Oncol. 2010;8:29.20398400
8. Sorbye H Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study Ann Oncol 2013 24 1 152 160 10.1093/annonc/mds276 22967994
Sorbye H, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.22967994
9. Alia Navarro V Localized colonic small-cell carcinoma with pathological complete response after neoadjuvant cisplatin and etoposide: a case report Curr Oncol 2023 30 9 8426 8433 10.3390/curroncol30090613 37754528
Alia Navarro V, et al. Localized colonic small-cell carcinoma with pathological complete response after neoadjuvant cisplatin and etoposide: a case report. Curr Oncol. 2023;30(9):8426–33.37754528
10. Miyamoto H Poorly differentiated neuroendocrine cell carcinoma of the rectum: report of a case and literal review J Med Invest 2006 53 3–4 317 320 10.2152/jmi.53.317 16953071
Miyamoto H, et al. Poorly differentiated neuroendocrine cell carcinoma of the rectum: report of a case and literal review. J Med Invest. 2006;53(3–4):317–20.16953071
11. Erstad DJ Prognosis for poorly differentiated, high-grade rectal neuroendocrine carcinomas Ann Surg Oncol 2022 29 4 2539 2548 10.1245/s10434-021-11016-8 34787737
Erstad DJ, et al. Prognosis for poorly differentiated, high-grade rectal neuroendocrine carcinomas. Ann Surg Oncol. 2022;29(4):2539–48.34787737
12. Mao R Adjuvant chemotherapy versus observation following resection for patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas Ann Surg 2021 274 2 e126 e133 10.1097/SLA.0000000000003562 31478977
Mao R, et al. Adjuvant chemotherapy versus observation following resection for patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas. Ann Surg. 2021;274(2):e126–33.31478977
13. Strosberg JR The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 2010 39 6 799 800 10.1097/MPA.0b013e3181ebb56f 20664477
Strosberg JR, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800.20664477
14. Noda K Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 2002 346 2 85 91 10.1056/NEJMoa003034 11784874
Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91.11784874
15. Satake M A case of neuroendocrine carcinoma of the ascending colon that responded completely to chemotherapy Gan To Kagaku Ryoho 2018 45 10 1513 1515 30382062
Satake M, et al. A case of neuroendocrine carcinoma of the ascending colon that responded completely to chemotherapy. Gan To Kagaku Ryoho. 2018;45(10):1513–5.30382062
16. Kim HG A case of large cell neuroendocrine carcinoma of the colon Korean J Gastroenterol 2009 54 1 46 49 10.4166/kjg.2009.54.1.46 19696550
Kim HG, et al. A case of large cell neuroendocrine carcinoma of the colon. Korean J Gastroenterol. 2009;54(1):46–9.19696550
